Catalogued
University of Colorado Boulder, Institute of Cognitive Science – CU Change
This dataset was collected from 2017–2022 on adults living in the Denver/Boulder area with at least mild anxiety symptoms who were either regular cannabis users or had not used in the past 6 months. Participants were divided into four groups: 1) cannabis users randomly assigned to a THC-dominant product, 2) users randomly assigned to a balanced THC:CBD product, 3) users randomly assigned to a CBD-dominant product, and 4) non-users who served as a comparison group. Data was then collected on participants over the course of 4 weeks as they consumed their assigned legal market flower ad libitum, with measures collected on demographics, psychiatric symptoms, substance use, blood cannabinoid levels, and acute mood/drug effects before and after use of product during a mobile laboratory visit.
Top validated assessments include: AUDIT, BDI-II, MWC, MCQ, STAI, ASRS, PSS, RSRS, GAD-7, BAI, MDS, TLFB, DASS, L-CAT, DEQ, ARCI/M-Scale, Dot Probe Task, NCB, ISLT, EATS, RI, PANAS, and POMS.
Date range, conditions covered and surveys completed are not published for a single study: the public aggregate carries a participant count only. Repository-wide breakdowns are on the statistics page.
Last refreshed 5 minutes ago.
Aggregate counts only. Groups smaller than 10 are shown as a range.
Administered jointly by Realm of Caring and Johns Hopkins University under NIH award 1UM1DA059000 (NIDA).
